Iovance Biotherapeutics Stock Filter Stocks by Fundamentals
| IOVA Stock | USD 3.13 0.64 25.70% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Iovance Biotherapeutics' long-term financial health and intrinsic value.
Iovance | Shares Owned by Institutions | Build AI portfolio with Iovance Stock |
Iovance Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iovance Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iovance Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Iovance Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Iovance Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Iovance Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iovance Biotherapeutics' value.| Shares | Invenomic Capital Management, Lp | 2025-03-31 | 5.5 M | Macquarie Group Ltd | 2025-03-31 | 4.8 M | Principal Financial Group Inc | 2025-03-31 | 4.7 M | Artisan Partners Limited Partnership | 2025-03-31 | 4.4 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 4 M | Renaissance Technologies Corp | 2025-03-31 | 3.5 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 3.5 M | Palo Alto Investors, Llc | 2025-03-31 | 3.2 M | Bank Of America Corp | 2025-03-31 | 3 M | Vanguard Group Inc | 2025-03-31 | 27.8 M | Mhr Fund Management Llc | 2025-03-31 | 24.4 M |
Iovance Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.76) % | ||||
| Operating Margin | (2.46) % | ||||
| Current Valuation | 438.68 M | ||||
| Shares Outstanding | 333.93 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 81.25 % | ||||
| Number Of Shares Shorted | 96.78 M | ||||
| Price To Earning | (3.51) X | ||||
| Price To Book | 0.97 X | ||||
| Price To Sales | 3.91 X | ||||
| Revenue | 164.07 M | ||||
| Gross Profit | 46.2 M | ||||
| EBITDA | (351.67 M) | ||||
| Net Income | (372.18 M) | ||||
| Cash And Equivalents | 424.46 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 58.26 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 2.30 X | ||||
| Cash Flow From Operations | (352.98 M) | ||||
| Short Ratio | 6.77 X | ||||
| Earnings Per Share | (1.22) X | ||||
| Target Price | 10.7 | ||||
| Number Of Employees | 838 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 831.5 M | ||||
| Total Asset | 910.43 M | ||||
| Retained Earnings | (2.38 B) | ||||
| Working Capital | 334.68 M | ||||
| Current Asset | 290.82 M | ||||
| Current Liabilities | 10.12 M | ||||
| Net Asset | 910.43 M |
About Iovance Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iovance Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iovance Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iovance Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out Iovance Biotherapeutics Piotroski F Score and Iovance Biotherapeutics Altman Z Score analysis. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share | Quarterly Revenue Growth 67.985 | Return On Assets | Return On Equity |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.